SCHEMBL9944079

SCHEMBL9944079

Cc1cc(C(=O)Nc2ccc(C(=O)O)cc2)cc(Cl)c1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
PKM P14618 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MITF O75030 1/20 0.50
MAPT P10636 1/20 0.50
CPT2 P23786 1/20 0.49
CPT1A P50416 1/20 0.49
CPT1B Q92523 1/20 0.49
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
TAS1R2 Q8TE23 1/20 0.49
BCAT2 O15382 1/20 0.49
FFAR1 O14842 1/20 0.49
CA12 O43570 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
PTGER4 P35408 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944134 0.92 MEN1 (0.58) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944083 0.87 NPC1 (0.50) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944136 0.83 TAS1R3 (0.65) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944103 0.82 MAPT (0.50) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944098 0.82 PKM (0.60) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944085 0.82 NPC1 (0.57) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944078 0.81 TAS1R3 (0.52) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944095 0.81 RARA (0.52) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944088 0.81 NPC1 (0.53) KMT2AMEN1NPC1RAB9APKM
SCHEMBL9944081 0.80 TAS1R3 (0.51) KMT2AMEN1NPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG KMT2A 1418/4885MEN1 4809/4885NPC1 277/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG KMT2A 1418/4885MEN1 4809/4885NPC1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.